Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

As we enter a new earnings season, there are several reasons for optimism about the economy. However, potential headwinds ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Ticker: Wegovy and Zepbound prices fall; ExxonMobil and partner Qatar Energy find new natural gas deposit off Cyprus ...

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average, compared ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.